InnoCare Pharma Limited (9969.HK)
HKD 6.1
(0.16%)
HKD 6.1
(0.16%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.37 CNY | 37.29% |
| 2022 | -0.59 CNY | -1109.02% |
| 2021 | -0.05 CNY | 89.83% |
| 2020 | -0.48 CNY | 71.93% |
| 2019 | -1.71 CNY | -288.64% |
| 2018 | -0.44 CNY | -62.96% |
| 2017 | -0.27 CNY | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.08 CNY | -34.68% |
| 2024 Q2 | -0.07 CNY | 0.0% |
| 2023 FY | - CNY | 37.29% |
| 2023 Q4 | -0.06 CNY | 3.41% |
| 2023 Q3 | -0.06 CNY | 67.63% |
| 2023 Q1 | -0.01 CNY | 68.05% |
| 2023 Q2 | -0.19 CNY | -1800.0% |
| 2022 Q4 | -0.03 CNY | 88.82% |
| 2022 Q3 | -0.28 CNY | -16.67% |
| 2022 Q2 | -0.24 CNY | -200.0% |
| 2022 Q1 | -0.08 CNY | 20.0% |
| 2022 FY | - CNY | -1109.02% |
| 2021 Q1 | -0.08 CNY | -222.95% |
| 2021 Q3 | 0.21 CNY | 366.5% |
| 2021 Q4 | -0.10 CNY | -147.62% |
| 2021 Q2 | -0.08 CNY | 0.0% |
| 2021 FY | - CNY | 89.83% |
| 2020 FY | - CNY | 71.93% |
| 2020 Q1 | -0.22 CNY | 81.51% |
| 2020 Q3 | -0.02 CNY | 88.91% |
| 2020 Q2 | -0.22 CNY | 0.0% |
| 2020 Q4 | -0.02 CNY | 0.0% |
| 2019 Q3 | -0.27 CNY | 67.47% |
| 2019 Q2 | -0.83 CNY | 0.0% |
| 2019 Q1 | -0.83 CNY | -1067.37% |
| 2019 FY | - CNY | -288.64% |
| 2019 Q4 | -1.19 CNY | -340.74% |
| 2018 Q3 | -0.14 CNY | -29.46% |
| 2018 Q4 | -0.07 CNY | 50.97% |
| 2018 Q1 | -0.11 CNY | 0.0% |
| 2018 Q2 | -0.11 CNY | 0.0% |
| 2018 FY | - CNY | -62.96% |
| 2017 FY | - CNY | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 0.01 HKD | 3433.333% |
| CK Life Sciences Int'l., (Holdings) Inc. | 0.00 HKD | 20655.556% |